Minerva Neurosciences Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
Stock Information for Minerva Neurosciences Inc
Loading
Please wait while we load your information from QuoteMedia.